These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27282150)

  • 41. Hitting the (bio)mark part 2: analyzing, interpreting, and reporting biomarker data in cardiovascular research.
    Denfeld Q; Daelman B; Butts B
    Eur J Cardiovasc Nurs; 2024 Feb; ():. PubMed ID: 38366157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles.
    Padroni L; De Marco L; Fiano V; Milani L; Marmiroli G; Giraudo MT; Macciotta A; Ricceri F; Sacerdote C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BatMan: Mitigating Batch Effects Via Stratification for Survival Outcome Prediction.
    Ni A; Liu M; Qin LX
    JCO Clin Cancer Inform; 2023 Jun; 7():e2200138. PubMed ID: 37335961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On data normalization and batch-effect correction for tumor subtyping with microRNA data.
    Wu Y; Yuen BW; Wei Y; Qin LX
    NAR Genom Bioinform; 2023 Mar; 5(1):lqac100. PubMed ID: 36632610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depth normalization of small RNA sequencing: using data and biology to select a suitable method.
    Düren Y; Lederer J; Qin LX
    Nucleic Acids Res; 2022 Jun; 50(10):e56. PubMed ID: 35188574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Making External Validation Valid for Molecular Classifier Development.
    Wu Y; Huang HC; Qin LX
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance evaluation of transcriptomics data normalization for survival risk prediction.
    Ni A; Qin LX
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34245143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statistical Assessment of Depth Normalization for Small RNA Sequencing.
    Qin LX; Zou J; Shi J; Lee A; Mihailovic A; Farazi TA; Tuschl T; Singer S
    JCO Clin Cancer Inform; 2020 Jun; 4():567-582. PubMed ID: 32598180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CAncer bioMarker Prediction Pipeline (CAMPP)-A standardized framework for the analysis of quantitative biological data.
    Terkelsen T; Krogh A; Papaleo E
    PLoS Comput Biol; 2020 Mar; 16(3):e1007665. PubMed ID: 32176694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study Design Considerations for Cancer Biomarker Discoveries.
    Zheng Y
    J Appl Lab Med; 2018 Sep; 3(2):282-289. PubMed ID: 30828695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples.
    Qin LX; Huang HC; Villafania L; Cavatore M; Olvera N; Levine DA
    Sci Data; 2018 May; 5():180084. PubMed ID: 29762551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.
    Agapito G; Botta C; Guzzi PH; Arbitrio M; Di Martino MT; Tassone P; Tagliaferri P; Cannataro M
    Microarrays (Basel); 2016 Sep; 5(4):. PubMed ID: 27669316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
    Andorfer P; Heuwieser A; Heinzel A; Lukas A; Mayer B; Perco P
    BMC Syst Biol; 2016 Apr; 10():33. PubMed ID: 27090655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
    Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer.
    Qin LX; Levine DA
    BMC Med Genomics; 2016 Jun; 9(1):27. PubMed ID: 27282150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
    Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
    Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.